http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-202092891-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 2019-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-202092891-A1 |
| titleOfInvention | GIP / GLP1 COAGONISTS |
| abstract | The present invention relates to compounds having both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor activity. The present invention also relates to compounds having an increased duration of action at each of these receptors. In addition, the present invention relates to compounds that can be administered orally. The compounds may be useful in the treatment of type 2 diabetes mellitus ("T2DM"). Also, the compounds can be useful in the treatment of obesity. |
| priorityDate | 2018-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.